Bernard Thierry, a former director at Neogen Corp, has filed a notice to sell 16,937 shares of the company's common stock. This filing, made on October 28, 2026, follows the exercise of stock options, indicating a significant personal financial move by Thierry.

Neogen Corp, incorporated in Michigan, operates in the in vitro and in vivo diagnostic substances sector. The company is known for its focus on developing products for food and animal safety, making it a key player in the life sciences industry. The recent filing is part of Thierry's ongoing financial activities, as he transitions from his role within the company.

According to the filing, the shares are being sold through Fidelity Brokerage Services LLC, with an aggregate market value of approximately $206,520.92. The sale date is recorded as the same day as the filing, October 28, 2026. Thierry's decision to sell these shares may reflect personal financial strategies or changes in his investment portfolio.

This transaction could have implications for Neogen Corp as it continues to navigate the competitive landscape of the diagnostic substances market. While the filing does not specify the reasons behind Thierry's sale, it is common for former directors to adjust their holdings after leaving their positions. Investors and analysts may closely monitor such developments, as they can impact market perceptions of the company's stability and leadership.

Details were not available in the SEC filing regarding any future actions or additional filings related to Thierry's share sale. The filing primarily serves to inform the market of his current financial activities concerning Neogen Corp.